Ovid Therapeutics Inc (OVID) - Total Assets
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) holds total assets worth $150.93 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore OVID debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Ovid Therapeutics Inc - Total Assets Trend (2014–2025)
This chart illustrates how Ovid Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Ovid Therapeutics Inc (OVID) net assets for net asset value and shareholders' equity analysis.
Ovid Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Ovid Therapeutics Inc's total assets of $150.93 Million consist of 59.9% current assets and 40.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Ovid Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OVID stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ovid Therapeutics Inc's current assets represent 59.9% of total assets in 2025, a decrease from 99.8% in 2014.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, down from 99.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Ovid Therapeutics Inc Competitors by Total Assets
Key competitors of Ovid Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Ovid Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.91 | 5.32 | 14.48 |
| Quick Ratio | 10.91 | 5.32 | 14.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $82.16 Million | $45.42 Million | $220.32 Million |
Ovid Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Ovid Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.70 |
| Latest Market Cap to Assets Ratio | 2.91 |
| Asset Growth Rate (YoY) | 63.8% |
| Total Assets | $150.93 Million |
| Market Capitalization | $439.51 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Ovid Therapeutics Inc's assets at a significant premium (2.91x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ovid Therapeutics Inc's assets grew by 63.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ovid Therapeutics Inc (2014–2025)
The table below shows the annual total assets of Ovid Therapeutics Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $150.93 Million | +63.76% |
| 2024-12-31 | $92.17 Million | -36.01% |
| 2023-12-31 | $144.03 Million | -7.24% |
| 2022-12-31 | $155.27 Million | -20.19% |
| 2021-12-31 | $194.54 Million | +156.23% |
| 2020-12-31 | $75.93 Million | -6.08% |
| 2019-12-31 | $80.84 Million | +69.66% |
| 2018-12-31 | $47.65 Million | -46.73% |
| 2017-12-31 | $89.46 Million | +68.70% |
| 2016-12-31 | $53.03 Million | -24.65% |
| 2015-12-31 | $70.38 Million | +1348.65% |
| 2014-12-31 | $4.86 Million | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human or… Read more